ReviewBioMed research international2014
The role of MRI in prostate cancer active surveillance.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Prevalence of prostate cancer in PI-RADS version 2.1 T2-weighted transition zone 'nodule in nodule' and 'homogeneous mildly hypointense area between nodules' criteria: MRI-radical prostatectomy histopathological evaluation.European radiology · 2021Article
- Does a screening digital rectal exam provide actionable clinical utility in patients with an elevated PSA and positive MRI?BJUI compass · 2021Article
- Evaluation of relationships between the final Gleason score, PI-RADS v2 score, ADC value, PSA level, and tumor diameter in patients that underwent radical prostatectomy due to prostate cancer.La Radiologia medica · 2020Article
- Genomic Analysis of Localized High-Risk Prostate Cancer Circulating Tumor Cells at the Single-Cell Level.Cells · 2020Article
- Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression.Cancers · 2020Article
- Diagnosis of transition zone prostate cancer using T2-weighted (T2W) MRI: comparison of subjective features and quantitative shape analysis.European radiology · 2019Article
- Performance of T2 Maps in the Detection of Prostate Cancer.Academic radiology · 2019Article
- Article
- Performance of Ultrafast DCE-MRI for Diagnosis of Prostate Cancer.Academic radiology · 2018Article
- Combined PET/MRI: from Status Quo to Status Go. Summary Report of the Fifth International Workshop on PET/MR Imaging; February 15-19, 2016; Tübingen, Germany.Molecular imaging and biology · 2016Article
- MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer.International journal of molecular sciences · 2016Review
- Current role of multiparametric magnetic resonance imaging for prostate cancer.Quantitative imaging in medicine and surgery · 2015Review
- Current role of multiparametric magnetic resonance imaging in the management of prostate cancer.Korean journal of urology · 2015Review
- The role of magnetic resonance imaging in active surveillance of prostate cancer.Radiologia brasileiraReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Prostate cancer is the most common cancer diagnosis in American men, excluding skin cancer. The clinical behavior of prostate cancer varies from low-grade, slow growing tumors to high-grade aggressive tumors that may ultimately progress to metastases and cause death. Given the high incidence of men diagnosed with prostate cancer, conservative treatment strategies such as active surveillance are critical in the management of prostate cancer to reduce therapeutic complications of radiation therapy or radical prostatectomy. In this review, we will review the role of multiparametric MRI in the selection and follow-up of patients on active surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.